KUALA LUMPUR, 9 JUNE 2021 – In a new milestone move to boost Malaysia‘s digital health growth, Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”), a leading pharmaceutical company in Malaysia, has agreed to invest into Naluri Hidup Sdn. Bhd. (“Naluri”), a local digital health services provider, via a Series A funding round. Based on this agreement, Naluri will receive a total of USD500,000 from Duopharma Biotech to expand smart digital integrated health applications. This follows an initial investment of USD250,000 by Duopharma Biotech via a Simple Agreement for Future Equity (“SAFE”) made in April 2020 for a personalised digital holistic healthcare application. Additionally, Duopharma Biotech, as the returning strategic investor, together with other international and local venture capital firms will enable Naluri, which is a local pioneer in digital therapeutics, to expand operations into the region and deepens its data science capabilities.